21106727

Source:http://linkedlifedata.com/resource/pubmed/id/21106727

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0018270, umls-concept:C0205102, umls-concept:C0376358, umls-concept:C0560007, umls-concept:C1140168, umls-concept:C1513882, umls-concept:C1521828, umls-concept:C1522602, umls-concept:C1718423, umls-concept:C1720529, umls-concept:C1948059, umls-concept:C2348767
pubmed:issue	4
pubmed:dateCreated	2011-2-17
pubmed:abstractText	In solid tumors such as prostate cancer, novel paradigms are needed to assess therapeutic efficacy. We utilized a method estimating tumor growth and regression rate constants from serial PSA measurements, and assessed its potential in patients with metastatic castration resistant prostate carcinoma (mCRPC).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1078-0432
pubmed:author	pubmed-author:ArlenPhil MPM, pubmed-author:BatesSusan ESE, pubmed-author:DahutWilliamW, pubmed-author:FiggWilliam DWD, pubmed-author:FojoTitoT, pubmed-author:GulleyJames LJL, pubmed-author:MadanRavi ARA, pubmed-author:NingYang-MinYM, pubmed-author:PriceDougD, pubmed-author:SchlomJeffJ, pubmed-author:SteinWilfred DWD
pubmed:copyrightInfo	©2010 AACR.
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	907-17
pubmed:meshHeading	pubmed-meshheading:21106727-Adult, pubmed-meshheading:21106727-Aged, pubmed-meshheading:21106727-Aged, 80 and over, pubmed-meshheading:21106727-Algorithms, pubmed-meshheading:21106727-Clinical Trials, Phase II as Topic, pubmed-meshheading:21106727-Computer Simulation, pubmed-meshheading:21106727-Humans, pubmed-meshheading:21106727-Kaplan-Meier Estimate, pubmed-meshheading:21106727-Male, pubmed-meshheading:21106727-Middle Aged, pubmed-meshheading:21106727-Models, Biological, pubmed-meshheading:21106727-National Cancer Institute (U.S.), pubmed-meshheading:21106727-Orchiectomy, pubmed-meshheading:21106727-Prostate-Specific Antigen, pubmed-meshheading:21106727-Prostatic Neoplasms, pubmed-meshheading:21106727-Treatment Outcome, pubmed-meshheading:21106727-Tumor Burden, pubmed-meshheading:21106727-Tumor Markers, Biological, pubmed-meshheading:21106727-United States
pubmed:year	2011
pubmed:articleTitle	Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
pubmed:affiliation	Medical Oncology Branch and Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. tfojo@helix.nih.gov
pubmed:publicationType	Journal Article